Pharmaceutical Care to a Geriatric Syndrome Patient with Heart Failure Combined with Uremia

doi:10.19803/j.1672-8629.20240898

Chinese Journal of Pharmacovigilance ›› 2025, Vol. 22 ›› Issue (7): 805-808.
DOI: 10.19803/j.1672-8629.20240898

Previous Articles Next Articles

Pharmaceutical Care to a Geriatric Syndrome Patient with Heart Failure Combined with Uremia

LI Ying^1,2, HUANG Lishuang³, ZHANG Jingjing⁴, ZHU Yuanchao^2,*, SHEN Ji⁵, YANG Jun¹

¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
²Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, Beijing Hospital, Beijing 100730, China;
³Department of Pharmacy, Tangshan Workers’ Hospital, Tangshan Hebei 063000, China;
⁴Department of Pharmacy, Weifang People’s Hospital, Weifang Shandong 261041, China;
⁵Department of Geriatrics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Received:2024-11-25 Online:2025-07-15 Published:2025-07-17

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the geriatric treatment team based on pharmaceutical services to a geriatric syndrome patient with heart failure combined with uremia. Methods A clinical pharmacist participated in the whole process of diagnosis and treatment of this patient. This pharmacist observed pharmacokinetic-pharmacodynamic changes in this patient, recommended an individualized medication plan according to the Results of comprehensive assessment, and improved pharmaceutical care. Results Adjustment of medication based on the patient’s condition reduced adverse reactions and optimized the treatment regimen for a patient with geriatric syndromes. Giving tips about medication improved the patient’s compliance. Conclusion Clinical pharmacists can give full play to their expertise by recommending individualized medications, detecting adverse reactions quickly, preventing drug interactions and analyzing the process of medication. They can play an important role in ensuring the safety of medication and improving the compliance of elderly patients.

Key words: Heart Failure, Uremia, Hemodiafiltration, Comprehensive Geriatric Assessment

CLC Number:

R972

LI Ying, HUANG Lishuang, ZHANG Jingjing, ZHU Yuanchao, SHEN Ji, YANG Jun. Pharmaceutical Care to a Geriatric Syndrome Patient with Heart Failure Combined with Uremia[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 805-808.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240898

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I7/805

References

[1] YAN XL, DU GX, SUN XH.The Importance of Rational Medication for the Elderly[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2023, 26(5): 718-720.
[2] National Center for Cardiovascular Diseases, China National Heart Failure Society, Chinese Heart Failure Association of Chinese Medical Doctor Association, et al. China National Heart Failure Guideline 2023[J]. Chinese Journal of Heart Failure and Cardiomyopathy(中华心力衰竭和心肌病杂志), 2023, 7(4): 215-311.
[3] Chinese Society of Nephrology, Zhongguancun Nephrology & Blood Purification Innovation Alliance. Guidelines for the Management of Chronic Heart Failure in Dialysis Patients in China[J]. Chinese Journal of Nephrology(中华肾脏病杂志), 2022, 38(5): 465-496.
[4] ZOCCALI C, MALLAMACI F, PARLONGO S, et al.Plasma Norepi-nephrine Predicts Survival and Incident Cardiovascular Events in Patients with End-Stage Renal Disease[J]. Circulation, 2002, 105(11): 1354-1359.
[5] WEIR MA, DIXON SN, FLEET JL, et al.β-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis[J]. Journal of the American Society of Nephrology, 2015, 26(4): 987-996.
[6] LI Y, XIE N, LIANG M.Aldosterone Antagonists Reduce the Risk of Cardiovascular Mortality in Dialysis Patients: a Meta-Analysis[J]. Evidence-Based Complementary and Alternative Medicine, 2019, 2019(1): 1-9.
[7] AYALASOMAYAJULA SP, LANGENICKEL TH, JORDAAN P,et al.Effect of Renal Function on the Pharmacokinetics of LCZ696 (Sacu-bitril/Valsartan), an Angiotensin Receptor Neprilysin Inhibitor[J]. European Journal of Clinical Pharmacology, 2016, 72(9): 1065-1073.
[8] CHANG HY, FENG AN, FONG MC, et al.Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients: Real World Experience on Advanced Chronic Kidney Disease, Hypotension, and Dose Escalation[J]. Journal of Cardiology, 2019, 74(4): 372-380.
[9] LEE S, OH J, KIM H, et al.Sacubitril/Valsartan in (Patients with Heart Failure with Reduced Ejection Fraction with End-Stage Renal Disease)[J]. European Journal of Heart Failure, 2020, 7(3): 1125-1129.
[10] ZUO L, GAN LY, LV XX, et al.Application of Angiotensin Receptor-Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus[J]. Chinese Journal of Blood Purification(中国血液净化), 2023, 22(4): 241-253.
[11] The 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults[J]. Journal of the American Geriatrics Society, 2023, 71(7): 2052-2081.
[12] DENIS O’M, ANTONIO C, ANNA RG, et al.STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 3[J]. European Geriatric Medicine, 2023, 14(4): 625-632.
[13] Rational Drug Use Branch of Chinese Association of Geriatric Research. Griteria of Potentially Inappropriate Medications for Older Adults in China[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2018, 20(1): 2-8.
[14] FRANCO DC, GIAN LD, EDOARDO GO, et al.Comparative Effects of Pharmacological Interventions for the Acute and Long-Term Management of Insomnia Disorder in Adults: a Systematic Review and Network Meta-Analysis[J]. Lancet, 2022, 400(10347): 170-184.
[15] SHI H, ZHAO YJ, DENG LZ.Clinical Significance and Application Advances of Comprehensive Geriatric Assessment[J]. Chinese Journal of Cardiovascular Medicine(中国心血管杂志), 2021, 26(5): 413-417.

Pharmaceutical Care to a Geriatric Syndrome Patient with Heart Failure Combined with Uremia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Recommended Articles

Metrics

[1]	ZHANG Wei, XU Dongjie, JIN Yu, ZOU Ying, ZHANG Ting, ZHOU Jiancheng. One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 113-115.
[2]	ZHANG Jianwei, LIU Li, XU Guanglin, SHI Xiaoli. Lujiao Formula Inhibiting Cardiac Hypertrophy Induced by Ang Ⅱ through Regulating the NF-κB Pathways [J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1250-1255.
[3]	ZHU Yuanchao, ZHAO Ming, HU Xin, SHI Hong. Pharmacist-led practice in the management of elderly patients with polypharmacy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 817-821.
[4]	ZHANG Zhiwen, TANG Lihua. Suspected mental disorder in uremia hemodialysis induced by piperacillin sodium and sulbactam sodium for injection: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 588-590.
[5]	WANG Li, YU Wenwen, LI Min, GUO Ruihui, CAO Guangsheng, QI Yingmei. Risk factors and precautions for adverse drug reactions caused by Digoxin [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1269-1272.
[6]	SUN Chunquan, XIE Yanming, HOU Hengyue. Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
[7]	XIE Guanghui, MA Zengchun, MEI Yu, ZHANG Xuemei, TAN Hongling, GAO Yue. Evaluation of Pharmacokinetics of Aconiti Lateralis Radix of Shenfu Prescription in Rats with Heart Failure [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 632-636.
[8]	LI Li, ZHANG Dan, ZHOU Nan, ZHANG Peng, ZHU Yaning. Pharmaceutical Care of One Patient with Severe Acute Left Heart Failure Induced by Low-dose Epirubicin [J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1189-1191.
[9]	WANG Luyao, DENG Zhe, XIAO Suping, ZHANG Quan, OUYANG Luodan, CHEN Meng, ZHOU Haiyan, WANG Jiyong, DU Jie. Modern Clinical Applications and Analysis of Linggui Zhugan Decoction [J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1066-1069.
[10]	ZHANG Shengzhang, HUANG Weijian. Clinical Efficacy and Adverse Reaction of Torasemide Combined with Bisoprolol in the Treatment of Patients with Essential Hypertension Complicated with Systolic Heart Failure [J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 467-472.
[11]	WANG Tao, DONG Duo, XIONG Weiyi, TIAN Chunhua, LIU Hongliang. Risk Signals of Innovative Antineoplastic Drug Chidamide Tablets [J]. Chinese Journal of Pharmacovigilance, 2019, 16(10): 614-616.
[12]	LI Xiao-yu, LUAN Yong-fu, SUN Rong. Evaluation on the "Efficacy-toxicity" Correlation of Radix Aconiti Lateralis Praeparata on Spleen-kidney Yang Deficiency Rat with Heart Failure [J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 449-453.